This Article Abstract Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Januzzi, J. L. Articles by Wu, A. H.B. Search for Related Content PubMed Articles by Januzzi, J. L., Jr Articles by Wu, A. H.B.

Measurement of the Interleukin Family Member ST2 in Patients With Acute Dyspnea

Results From the PRIDE (Pro-Brain Natriuretic Peptide Investigation of Dyspnea in the Emergency Department) Study

James L. Januzzi, Jr, MD FACC^_*, W. Frank Peacock, MD^,_*, Alan S. Maisel, MD, FACC, Claudia U. Chae, MD, MPH, FACC^_*, Robert L. Jesse, MD, FACC, Aaron L. Baggish, MD^_*, Michelle O'Donoghue, MD^_*, Rahul Sakhuja, MD^_*, Annabel A. Chen, MD^_*, Roland R.J. van Kimmenade, MD^||, Kent B. Lewandrowski, MD^_*, Donald M. Lloyd-Jones, MD, MSc, FACC^¶ and Alan H.B. Wu, PhD^#

^_* Department of Medicine and Laboratory Medicine, Massachusetts General Hospital, Boston, Massachusetts
Department of Emergency Medicine, Cleveland Clinic Foundation, Cleveland, Ohio
Department of Medicine, University of California, San Diego, California
^# Department of Laboratory Medicine, University of California, San Francisco, California
Department of Medicine, Virginia Commonwealth University, Richmond, Virginia
^|| Department of Medicine, University Hospital Maastricht, Maastricht, the Netherlands
^¶ Department of Preventive Medicine and Bluhm Cardiovascular Institute, Northwestern University Feinberg School of Medicine, Chicago, Illinois. Drs. Januzzi, Peacock, Maisel, Jesse, and Wu have received consulting income from Critical Care Diagnostics, holder of the license for ST2 cardiac testing. Drs. Januzzi and Maisel have received grant support, consulting income, and speaking fees from Roche Diagnostics, Inc. Dr. E. Magnus Ohman served as Guest Editor for this article

View larger version (13K): [in this window] [in a new window] [Download PPT slide]   Figure 1 ST2 Concentrations at Presentation as a Function of Survival at 1 Year Medians are depicted; boxes represent the 25th and 75th percentile, whereas whiskers represent the 5th and 95th percentile.

View larger version (13K): [in this window] [in a new window] [Download PPT slide]   Figure 2 Rates of Death at 1 Year as a Function of ST2 Decile in Dyspneic Patients Rates of death at 1 year as a function of ST2 concentrations in dyspneic patients.

View larger version (15K): [in this window] [in a new window] [Download PPT slide]   Figure 3 Receiver-Operating Characteristic Analysis for ST2 and Death at 1 Year Receiver operating characteristic analysis with area under the curve (AUC) demonstrated for ST2 and death at 1 year after presentation with dyspnea. Candidate cut-points for ST2 are depicted. CI = confidence interval.

View larger version (13K): [in this window] [in a new window] [Download PPT slide]   Figure 4 Hazard Curves Depicting the Rates of Death From Presentation to 1 Year of Follow-Up Among dyspneic patients with ST2 concentrations 0.20 ng/ml, a high rate of mortality was noted among those (A) with and (B) without acute heart failure (all log-rank p values <0.001).

View larger version (28K): [in this window] [in a new window] [Download PPT slide]   Figure 5 Mortality Rates at 1 Year as a Function of ST2 and NT-proBNP Concentrations Mortality rates at 1 year as a function of ST2 and amino-terminal pro-brain natriuretic peptide (NT-proBNP) concentrations among (A) dyspneic patients with and without acute heart failure (HF) (n = 593) as well as (B) those with acute HF (n = 208).